Developing a precision immune tolerance platform with the aim of improving the lives of patients suffering from serious and debilitating diseases
Who we Are
Over a decade of experience pioneering precision immune tolerance
Selecta Biosciences Inc., founded in 2008, is leveraging its clinically validated ImmTOR® platform to develop antigen-specific tolerogenic therapies. With the potential ability to induce tolerance to highly immunogenic molecules, ImmTOR® aims to restore the body’s natural immune system balance by re-imagining immunotherapy for autoimmune disease, as well as unlock the potential of gene therapy and amplifying the efficacy of biologic therapy.
At Selecta, we strive toward a common goal: to use precision immune tolerance platforms to improve the lives of patients who suffer from serious and debilitating diseases.
What We Value
We are COLLABORATIVE
We tap into the diversity of thought and experience from each employee, learning from one another, to collectively produce meaningful results.
We are PIONEERING
We possess the intellectual curiosity to continually strengthen, evolve, and invest using data to solve problems.
We are PATIENT FOCUSED
We work on therapies to transform patient lives, looking to patient experiences to ground our motivations and decisions and to keep front of mind our potential impact.
Diversity & Inclusion
Selecta Biosciences is led by a group of veteran scientists and industry experts that have built a creative, diverse and engaging work environment that is embodied by the entirety of the team.
We leverage our diversity of thought to pioneer next-generation precision immune tolerance therapies, and our diversity of experiences to efficiently bring them to patients in need.
Our team’s combined talent and experience from across academia, biotech and large and small pharma positions Selecta as a powerhouse in precision immune tolerance fueled by our diverse collaborations and inclusive work environment.
At Selecta, we are pioneering precision immune tolerance by developing antigen-specific tolerogenic therapies with the potential to transform the lives of patients suffering from serious and debilitating diseases. By leveraging the power of our clinically validated ImmTOR® platform, we are re-imagining immunotherapy for autoimmune disease, unlocking the true potential of AAV gene therapy and amplifying the efficacy of biologic therapy. With our strong leadership and a diverse, collaborative and intellectually curious team, we are advancing numerous proprietary assets and have formed strategic partnerships with leading biopharmaceutical companies. Our patient-focus motivates us to continually advance our proprietary pipeline towards commercialization, but also work with our partners to maximize the reach and potential benefit of ImmTOR®.
Selecta is led by an experienced and skilled team, all working toward the goal of restoring natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.
Board of Directors
Selecta’s board of directors consists of skilled industry experts with extensive expertise in immunology, biology, pharmaceuticals and drug development.
Timothy springer, PH.D.
Professor, Harvard Medical School and Children’s Hospital Boston
Careers at Selecta
At Selecta, we’re constantly seeking talented individuals who are ready to share their skills, creativity and passion to help us advance our precision immune tolerance therapies that will transform the lives of patients.